Literature DB >> 10957839

Cardiac abnormalities in birth asphyxia.

M S Ranjit1.   

Abstract

Cardiac abnormalities in birth asphyxia were first recognised in the 1970s. These include (i) transient tricuspid regurgitation which is the commonest cause of a systolic murmur in a newborn and tends to disappear without any treatment unless it is associated with transient myocardial ischemia or primary pulmonary hypertension of the newborn (ii) transient mitral regurgitation which is much less common and is often a part of transient myocardial ischemia, at times with reduced left ventricular function and, therefore, requires treatment in the form of inotropic and ventilatory support (iii) transient myocardial ischemia (TMI) of the newborn. This should be suspected in any baby with asphyxia, respiratory distress and poor pulses, especially if a murmur is audible. It is of five types (A to E) according to Rowe's classification. Type B is the most severe with respiratory distress, congestive heart failure and shock. Echocardiography helps to rule out critical left ventricular obstructive lesions like hypoplastic left heart syndrome or critical aortic stenosis. ECG is very important for diagnosis of TMI, and may show changes ranging from T wave inversion in one lead to a classical segmental infarction pattern with abnormal q waves. CPK-MB may rise and echocardiogram shows impaired left ventricular function, mitral and/or tricuspid regurgitation, and at times, wall motion abnormalities of left ventricle. Ejection fraction is often depressed and is a useful marker of severity and prognosis. Treatment includes fluid restriction, inotropic support, diuretics and ventilatory resistance if required (v) persistent pulmonary hypertension of the newborn (PPHN). Persistent hypoxia sometimes results in persistence of constricted fetal pulmonary vascular bed causing pulmonary arterial hypertension with consequent right to left shunt across patent ductus arteriosus and foramen ovale. This causes respiratory tension and right ventricular failure with systolic murmur of tricuspid, and at times, mitral regurgitation. Treatment consists of oxygen and general care for mild cases, ventilatory support, ECMO and nitric oxide for severe cases. Cardiac abnormalities in asphyxiated neonates are often underdiagnosed and require a high index of suspicion. ECG and Echo help in early recognition and hence better management of these cases.

Entities:  

Mesh:

Year:  2000        PMID: 10957839     DOI: 10.1007/bf02760486

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  10 in total

1.  [Transient myocardial ischemia in newborn infants].

Authors:  O Farru; M Rizzardini; N Guzman
Journal:  Arch Mal Coeur Vaiss       Date:  1986-05

2.  Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group.

Authors:  D Davidson; E S Barefield; J Kattwinkel; G Dudell; M Damask; R Straube; J Rhines; C T Chang
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

3.  Multiple organ involvement in perinatal asphyxia.

Authors:  A Martín-Ancel; A García-Alix; F Gayá; F Cabañas; M Burgueros; J Quero
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

4.  [Transient myocardial ischemia in newborn babies with perinatal asphyxia (hypoxic cardiomyopathy)].

Authors:  G Flores-Nava; J L Echevarría-Ybargüengoitia; J L Navarro-Barrón; A García-Alonso
Journal:  Bol Med Hosp Infant Mex       Date:  1990-12

5.  Persistence of atrioventricular valve regurgitation and electrocardiographic abnormalities following transient myocardial ischemia of the newborn.

Authors:  S O Turner-Gomes; T Izukawa; R D Rowe
Journal:  Pediatr Cardiol       Date:  1989       Impact factor: 1.655

6.  Transient myocardial ischemia of the newborn infant demonstrated by thallium myocardial imaging.

Authors:  J P Finley; R B Howman-Giles; D L Gilday; K R Bloom; R D Rowe
Journal:  J Pediatr       Date:  1979-02       Impact factor: 4.406

7.  Ischemic papillary muscle necrosis in stressed newborn infants.

Authors:  W H Donnelly; R L Bucciarelli; R M Nelson
Journal:  J Pediatr       Date:  1980-02       Impact factor: 4.406

8.  Nonstructural heart disease in the newborn. Observations during one year in a perinatal service.

Authors:  R D Rowe; T Izukawa; H C Mulholland; K R Bloom; D H Cook; P R Swyer
Journal:  Arch Dis Child       Date:  1978-09       Impact factor: 3.791

9.  Myocardial ischaemia in asphyxia neonatorum. Electrocardiographic, enzymatic and histological correlations.

Authors:  R A Primhak; R Jedeikin; G Ellis; S K Makela; J E Gillan; P R Swyer; R D Rowe
Journal:  Acta Paediatr Scand       Date:  1985-07

10.  Cardiogenic shock associated with perinatal asphyxia in preterm infants.

Authors:  L A Cabal; U Devaskar; B Siassi; J E Hodgman; G Emmanouilides
Journal:  J Pediatr       Date:  1980-04       Impact factor: 4.406

  10 in total
  4 in total

1.  Restoration of cardiopulmonary function with 21% versus 100% oxygen after hypoxaemia in newborn pigs.

Authors:  D Fugelseth; W B Børke; K Lenes; I Matthews; O D Saugstad; E Thaulow
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-05       Impact factor: 5.747

2.  Cardiac output, pulmonary artery pressure, and patent ductus arteriosus during therapeutic cooling after global hypoxia-ischaemia.

Authors:  D Fugelseth; S Satas; P A Steen; M Thoresen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-05       Impact factor: 5.747

3.  Assessment of left atrial ejection force in mildly asphyxiated newborns.

Authors:  Abdolrazagh Kiani; Reza Shabanian; Mahsa Rekabi; Armen Kocharian; Giv Heidari-Bateni
Journal:  Iran J Pediatr       Date:  2012-12       Impact factor: 0.364

Review 4.  Understanding the Full Spectrum of Organ Injury Following Intrapartum Asphyxia.

Authors:  Domenic A LaRosa; Stacey J Ellery; David W Walker; Hayley Dickinson
Journal:  Front Pediatr       Date:  2017-02-17       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.